Actos News | Bladder Cancer
Actos News
  • Watson Pharmaceuticals Joining the Generic Actos Parade

    IN August, when Takeda's patent on the diabetic drug Actos expired, the Food and Drug Administration (FDA) granted three pharmaceutical firms – Mylan, Ranbaxy and Teva – authorization  to market their own generic version of the medication. One company's application was denied, however. That company – Watson Pharmaceutical – filed a lawsuit against the FDA in response.

    read more
  • Why Big Pharma Keeps Doing It

    It is no secret that the large pharmaceutical corporations have been caught with their pants down on numerous occasions over the past several years – and the situation just keeps getting worse. Recently, Boston University law professor Kevin Outterson prepared a compilation of data on “major violations” by major drug companies. His report included Glaxo-Smith-Kline (GSK), manufacturer of the diabetic drug Avandia – shown to significantly increase the chances of cardiac arrest. 

    read more
  • Pennsylvania Researchers Confirm What We Already Know About Bladder Cancer And Actos

    This past August, yet another study was published demonstrating the increased risk of bladder cancer resulting from long-term use of thiazolidinedione drugs such as Actos and Avandia. This study, which came from the Perelman School of Medicine at the University of Pennsylvania, showed that 17 patients out of 10,000 taking these drugs are likely to develop bladder cancer. Diabetics are already at a higher risk, with about 4 out of 10,000 ultimately developing the disease as opposed to 3 out of 10,000  among the general population.

    read more
  • Cheaper Actos is Not Better

    Recently, the U.S. Food and Drug Administration approved a generic form of the diabetic drug, Actos – despite the fact that it has been proven to cause dangerous side effects. It would seem likely that availability of the less expensive form of the drug would encourage greater use. However, according to Consumer Reports, the nearly $380 single prescription price is not likely to drop anytime soon; at present, only three manufacturers have been authorized to produce generic versions.

    read more
  • Actos Bladder Cancer is Confirmed

    A recent study published in the British Medical Journal once again demonstrates a connection between use of the diabetes drug Actos (pioglitazone) and bladder cancer. Furthermore, a patient who has used the  medication for two years or longer is almost twice as likely to develop the disease.

    read more
  • Evidence Continues to Mount Against Takeda’s High Cancer Risk Drug

    A recent study in the British Medical Journal confirms that Actos is associated with an increased risk of bladder cancer, making the drug a very risky option for Type 2 diabetics.  The study, published on May 31st, involved a nested case-control design using the UK’s general practice database, the world’s largest computerized database of longitudinal records from primary care.  The cohort was populated with a database of medicated diabetics, and spanned a time period of over twenty years (1988 to 2009).  The results confirmed that use of Actos increases a patient’s cancer risk, s

    read more
  • Takeda Pharmaceuticals: What Didn't They Know (And When Did They Decide They Didn't Know It)?

    It's a sad and all-too common story, particularly in the pharmaceutical industry. They know there is a risk or potentially dangerous side effect to one of their profitable products and they don't yank it off the market (at least until they are forced to – either for legal or economic reasons). Instead, the company's bean counters crunch some numbers and decide how much a few legal settlements would cost versus how much profits would suffer if the product was recalled or the problem addressed.

    read more